Else Nutrition Holdings Inc. (TSXV:BABY) (OTCPK:BABYF) has become one of Rich’s biggest winners. Since he first profiled the company back in October, BABY has been on a tear, growing from $0.31 on October 17 to $0.89 today. That’s 187% worth of value added in just over three months!
A good deal of that growth arrived in the last week, meaning BABY is in the middle of another big growth spurt. Now, as it nears the $1.00 mark, Rich is putting the stock on full alert.
“I said they’re going to $1.00 because they’re changing the world,” he says. “When it hits $1.00, they will officially be up 250% since I first brought them to you.”
Else Nutrition’s Latest News
Yesterday, Else announced that it entered into an investment agreement with NewH2 Limited.
A subsidiary of Health and Happiness International Holdings Limited, which trades on the Hong Kong Stock Exchange, NewH2 has agreed to invest C$5.75 million in Else Nutrition. This agreement is part of an aggregate private placement offering of up to C$8.0 million.
Else says that it will use these proceeds to accelerate its US launch in Q2, 2020.
Else will also dedicate the newfound funds to enhancing its toll manufacturing capabilities and to build its distribution relationship with H&H and expedite sales in the new territories. Finally, the company plans to undertake additional marketing initiatives prior to launch.
CEO and Co-Founder of Else Nutrition, Hamutal Yitzhak, says of the agreement:
“We are thrilled about this relationship, and about the strong alignment between Else Nutrition and the H&H group. The strategic alignment with such a reputable, global and premium, health and wellness brand-builder, coupled with the investment, provide growth potential for our brand globally. It marks a significant milestone in our mission to change the way we feed our babies and families for generations to come, using real, clean, plant-based alternatives.”
Else Nutrition Will Operate in Both Infant and Adult Markets
As Rich reported last month, the company received a notice of allowance from the US Patent & Trademark Office to extend its existing patents to cover the adult market for malnutrition.
Else Nutrition’s formula consists of only three primary ingredients: tapioca, almonds, and buckwheat. Because of this, it provides the necessary proteins, amino acids, and other required nutrients for adults who have specific malnutrition-related conditions such as lean body mass and declining basal metabolic rates. And it does all this in a single food serving.
The infant formula market alone is expected to be worth US$103.75 billion by 2026. As Else will provide the only non-dairy, non-soy-based infant formula, it’ll likely capture a sizeable portion of the market.
In addition, it’s made using a clean, chemical-free process. This keeps the formula free of GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens.
BABY’s formula is the best choice for health-conscious parents and adults with malnutrition. Clearly, Rich believes the company is also a good choice for investors looking to get in on the revolutionary plant-based stock trend.
What do you think? Is BABY a good play? Will it hit $1.00 in the next month? Let us know your take!
Featured image: DepositPhotos © zmijak